Table 1.
Demographic and Medical Status of Clinically Referred Breast Cancer Patients.
| Demographics | Mean (SD) or N (%) or Range |
|---|---|
| Age, y | 47.79 (13.37) |
| Education, y | 16.76 (2.05) |
| Race | |
| Caucasian | 48 (75%) |
| Asian | 7 (11%) |
| African American | 8 (13%) |
| Hispanic | 1 (1%) |
| Premorbid Estimate (Standard Score) | 110 (9.31)† |
| Time between CT and testing (CT treated) | Median = 18 (0–163) |
| BDI Fast Screen Score (Raw Score) | 4.03 (3.39) |
| Memory Complaint | 56 (88%)†† |
|
| |
| Medical Variables | N (%) |
|
| |
| Disease Stage | |
| 0 | 1 (2%) |
| I | 23 (36%) |
| II | 19 (30%) |
| III | 10 (16%) |
| IV | 2 (3%) |
| No stage recorded | 9 (13%) |
| Surgery | |
| Lumpectomy | 15 (23%) |
| Mastectomy | 41 (73%) |
| Bilateral/Radical | 8 (13%) |
| Radiation | 41 (64%) |
| Chemotherapy and Radiation | 34 (53%) |
| Chemotherapy Length (in months) | 5.80 (0–27) |
| Chemotherapy | |
| ACT | 30 (47%) |
| Other | 10 (16%) |
| CMF | 10 (16%) |
| None | 13 (20%) |
| Chemotherapy regimen not recorded | 1(1%) |
| Endocrine Therapy at Time of NP Testing | 39 (61%) |
| Tamoxifen (Novadex)* | 17(27%)* |
| Arimidex (Anastrozole) | 15 (23%) |
| Letrozole (Femara) | 7 (11%) |
| Menopausal Status | |
| Premenopausal | 31 (48%) |
| Perimenopausal | 4 (6%) |
| Menopause | 25 (40%) |
| No Status recorded | 4 (6%) |
*
Two participants were also receiving Lupron
†
Based on either the WRAT-Reading; Wechsler Test of Adult Reading; or Test of Premorbid Functioning
††
Based on subject report of primary complaint